Skip to main content

Advertisement

SpringerLink
Log in

Durvalumab and multiple sclerosis: a causal link or simple unmasking?

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M (2015) Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3:1052–1062

    Article  CAS  Google Scholar 

  2. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982

    Article  CAS  Google Scholar 

  3. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Article  CAS  Google Scholar 

  4. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, Caputo D, Borelli M, Clerici M (2009) Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 183:4984–4993

    Article  CAS  Google Scholar 

  5. Kroner A, Schwab N, Ip CW, Ortler S, Göbel K, Nave KA, Mäurer M, Martini R, Wiendl H (2009) Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am J Pathol 174:2290–2299

    Article  CAS  Google Scholar 

  6. Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13(12):755–763

    Article  CAS  Google Scholar 

  7. Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol 21:1336–1342

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy

    Francesca Caputo, Alessia Manni, Pietro Iaffaldano, Maria Trojano & Damiano Paolicelli

Authors
  1. Francesca Caputo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessia Manni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pietro Iaffaldano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Trojano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Damiano Paolicelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Damiano Paolicelli.

Ethics declarations

Conflict of interest

F. Caputo and A. Manni report no disclosures relevant to the manuscript.

P. Iaffaldano received advisory board membership, speaker honoraria, travel support, research grants, consulting fees, or clinical trial support from Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, and Teva.

M. Trojano received advisory board membership, speaker honoraria, travel support, research grants, consulting fees, or clinical trial support from Actelion, Allergan, Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, and Teva.

D. Paolicelli received advisory board membership, speaker honoraria, travel support, research grants, consulting fees, or clinical trial support from Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, and Teva.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Caputo, F., Manni, A., Iaffaldano, P. et al. Durvalumab and multiple sclerosis: a causal link or simple unmasking?. Eur J Clin Pharmacol 76, 1773–1774 (2020). https://doi.org/10.1007/s00228-020-02959-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-02959-0

Search

Navigation